In the field of bio-pharmaceuticals, some domestic innovative drugs have demonstrated performance comparable to those of international pharmaceutical companies in terms of therapeutic effectiveness.In recent years, more and more international pharmaceutical companies have invested huge amounts in cooperation with Chinese pharmaceutical companies.

Earlier this year, China's artificial intelligence model DeepSeek gained world attention with extremely low development costs and strong performance, while in the field of biotechnology, China is also marking a similar "DeepSeek moment", China's pharmaceutical companies are entering from the past drug replication era to the era of innovative drugs, and attracted numerous international cooperation.

From a macro perspective, a report released by DealForma, an American biomedical data company, in May this year showed that Chinese biomedical companies have accounted for 42% in terms of quantity of large-scale global licensing transactions, that is, transactions with a down payment of US $50 million or more. This proportion has increased significantly compared with 27% last year and 20% the year before.

Some prominent cases, such as the first payment of $12.5 billion paid by Pfizer in May this year to obtain a license for an innovative drug in the overseas market. Additionally, in the first half of this year, US pharmaceutical companies Abbey, Mercedon and Regeneration, etc., and Chinese pharmaceutical companies signed billions of dollars worth of licensing cooperation agreements.

It is worth mentioning that the pharmaceutical company Aslikon, in the past two years has reached authorized cooperation with more than a dozen Chinese innovative pharmaceutical companies.

The industry insiders pointed out that the breakthrough in China's biotechnology industry today is the result of the continuous investment of Chinese governments and enterprises over the past few years.

Founder, Bisheng Asset Management, Singapore Wang GuohuiThe Chinese government is aware that it is necessary to encourage bio-pharmaceutical companies to increase their investment in innovation, and this work has actually been ongoing for years, so I think we will see many achievements and advances in the bio-pharmaceutical field in China in the coming years.

Jeffrey analysts pointed out that from the perspective of international pharmaceutical companies, they are currently facing the pressure of lowering the price of drugs, as well as the challenges of expired drug patents.